NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market
NurExone and Inteligex Kick Off Chronic Spinal Cord Injury Research for Multi-Billion Dollar Healthcare Market
TORONTO and HAIFA, Israel, Jan. 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (NRX.V) (the "Company" or "NurExone"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spinal cord injuries, is pleased to share several updates.
多伦多和以色列海法,2024年1月17日(GLOBE NEWSWIRE)——为脊髓外伤患者开发生物引导外泌体疗法的生物制药公司NurexOne Biologic Inc.(多伦多证券交易所股票代码:NRX)(FSE:J90)(“公司” 或 “NurexOne”)很高兴分享几项最新消息。
The collaborative agreement between NurExone and Inteligex Inc. ("Inteligex"), announced in October 2023, to expand the Company's portfolio, is now officially underway. This collaboration, aimed at combining Inteligex's more than twenty years of experience in cell-based therapies and NurExone's innovative exosome platform to develop therapies for patients with chronic spinal cord injuries, was approved for grant funding, to be disbursed over the course of the next two years, by the Israel-Canada bilateral Eureka program.
NurexOne与Inteligex Inc.(“Inteligex”)于2023年10月宣布的扩大公司投资组合的合作协议现已正式生效。这项合作旨在将Inteligex在细胞疗法领域二十多年的经验与NurexOne为慢性脊髓损伤患者开发疗法的创新外泌体平台相结合,已获得以色列-加拿大双边尤里卡计划批准的拨款,将在未来两年内发放。
Dr. Lior Shaltiel, CEO of NurExone, expressed his excitement about the kick-off of this project stating, "This collaboration reiterates the importance and utility of the ExoTherapy platform in developing drug delivery systems of the future. As part of this collaboration, we will use our platform to produce and load exosomes from Inteligex's cell line to deliver combination regenerative therapy for Spinal Cord Injury (SCI) patients. This win-win collaboration will expand our potential markets and is in line with our belief of patient, first."
NurexOne首席执行官Lior Shaltiel博士对该项目的启动表示兴奋,他说:“这次合作重申了Exotherapy平台在开发未来药物递送系统中的重要性和实用性。作为此次合作的一部分,我们将使用我们的平台从Inteligex的细胞系中生产和加载外泌体,为脊髓损伤(SCI)患者提供联合再生疗法。这种双赢合作将扩大我们的潜在市场,也符合我们以患者为先的信念。”
Dr. Paul Bradshaw, CEO of Inteligex, stated that "Spinal cord injury is the single most expensive healthcare condition in the world. I believe that a combinatorial multi-faceted approach to treatment of chronic SCI like the one in this project can both make a difference in patient's lives and save the healthcare system billions of dollars. Moreover, if the therapy has an easy delivery method, we can expand to countries where there is a massive barrier to any therapy or treatment and do a bit of good for humanity."
Inteligex首席执行官保罗·布拉德肖博士表示:“脊髓损伤是世界上最昂贵的医疗保健疾病。我相信,像这个项目那样采用多方面的组合方法来治疗慢性脊髓损伤,既可以改变患者的生活,又可以为医疗系统节省数十亿美元。此外,如果该疗法具有易于实施的方法,我们可以扩展到任何疗法或治疗都存在巨大障碍的国家,并为人类带来一点好处。”
NurExone Announces Engagement Agreement with bullVestor
NurexOne 宣布与 BullveStor 签订订合作协议
The Company has entered into an agreement (the "Agreement") with bullVestor Medien GmbH ("BullVestor") to assist with and enhance awareness of the Company's products and services using advertising and communications, some of which may constitute investor relations activities pursuant to the policies of the TSX Venture Exchange. The advertising and communications will occur in German-speaking countries (Germany, Austria and Switzerland).
公司已与BullveStor Medien GmbH(“BullveStor”)签订协议(“协议”),以利用广告和传播来协助和提高人们对公司产品和服务的认识,根据多伦多证券交易所风险交易所的政策,其中一些可能构成投资者关系活动。广告和传播将在德语国家(德国、奥地利和瑞士)进行。
The Agreement is effective for four months from the effective date and the total consideration payable to BullVestor is CAD$300,000 on the effective date. The consideration does not include any securities of the Company. BullVestor does not have any interest, directly or indirectly, in the Company or its securities, or any right or intent to acquire such an interest. Aside from this engagement, the Company does not have any relationship with BullVestor.
该协议自生效之日起四个月内生效,自生效之日起,应付给BullveStor的总对价为300,000加元。该对价不包括本公司的任何证券。BullveStor在公司或其证券中没有任何直接或间接的权益,也没有任何收购此类权益的权利或意图。除此次合作外,该公司与BullveStor没有任何关系。
BullVestor is located in Austria.
BullVestor 位于奥地利。
About NurExone Biologic Inc.
关于 Nurexone Biologic Inc.
NurExone Biologic Inc. is a TSXV listed pharmaceutical company that is developing a platform for biologically-guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries. ExoTherapy was conceptually demonstrated in animal studies at the Technion, Israel Institute of Technology. NurExone is translating the treatment to humans, and the company holds an exclusive worldwide license from the Technion and Tel Aviv University for the development and commercialization of the technology.
NurexOne Biologic Inc. 是一家在多伦多证券交易所上市的制药公司,该公司正在开发一个平台,以非侵入性方式向遭受创伤性脊髓损伤的患者提供生物引导的exOtherapy。exOtherapy在以色列理工学院的动物研究中得到了概念性的证实。NurexOne正在将这种治疗方法转化为人类,该公司拥有理工学院和特拉维夫大学颁发的全球独家许可,用于该技术的开发和商业化。
For additional information, please visit or follow NurExone on LinkedIn, Twitter, Facebook, or YouTube.
For more information, please contact:
欲了解更多信息,请访问 或者关注 NurexOne 领英, 推特, Facebook,或 优酷。
欲了解更多信息,请联系:
Dr. Lior Shaltiel
Chief Executive Officer and Director
Phone: +972-52-4803034
Email: info@nurexone.com
Lior Shaltiel 博士
首席执行官兼董事
电话:+972-52-4803034
电子邮件:info@nurexone.com
Thesis Capital Inc.
Investment Relation - Canada
Phone: +1 905-347-5569
Email: IR@nurexone.com
论文资本公司
投资关系-加拿大
电话:+1 905-347-5569
电子邮件:IR@nurexone.com
Dr. Eva Reuter
Investment Relation - Germany
Phone: +49-69-1532-5857
Email: e.reuter@dr-reuter.eu
伊娃·路透博士
投资关系-德国
电话:+49-69-1532-5857
电子邮件:e.reuter@dr-reuter.eu
FORWARD-LOOKING STATEMENTS
前瞻性陈述
This press release contains certain "forward-looking statements", that reflect the Company's current expectations and projections about its future results. Wherever possible, words such as "may", "will", "should", "could", "expect", "plan", "intend", "anticipate", "believe", "estimate", "predict" or "potential" or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements relating to the collaboration project with Inteligex and the grant funding pursuant thereto; the Agreement, the term of the Agreement and the fees payable thereunder. These statements reflect management's current beliefs and are based on information currently available to management as at the date hereof.
本新闻稿包含某些 “前瞻性陈述”,反映了公司当前对其未来业绩的预期和预测。尽可能使用诸如 “可能”、“将”、“应该”、“可以”、“期望”、“计划”、“打算”、“预测”、“相信”、“估计” 或 “潜在” 等词语或这些词语的负面或其他变体,或类似的词语或短语来识别这些前瞻性陈述。本新闻稿中的前瞻性陈述包括但不限于与Inteligex合作项目及根据该项目提供的补助金相关的陈述;协议、协议条款以及根据协议应付的费用。这些陈述反映了管理层当前的信念,并基于截至本文发布之日管理层目前获得的信息。
In developing the forward-looking statements in this press release, we have applied several material assumptions, including the general business and economic conditions of the industries and countries in which we operate, the general market conditions, the ability to secure additional funding for the collaboration with Inteligex and our ability to work collaboratively with Inteligex.
在撰写本新闻稿中的前瞻性陈述时,我们运用了多个重要假设,包括我们经营的行业和国家的总体商业和经济状况、总体市场状况、为与Inteligex合作获得额外资金的能力以及我们与Inteligex合作的能力。
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to the Company's early stage of development, lack of revenues to date, government regulation, market acceptance for its products, rapid technological change, dependence on key personnel, protection of the Company's intellectual property, dependence on the Company's strategic partners and the risks discussed under the heading "Risk Factors" on pages 29 to 36 of the Company's Annual Information Form dated March 30, 2023, a copy of which is available under the Company's SEDAR+ profile at . These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, the Company cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
前瞻性陈述涉及重大风险、不确定性和假设。许多因素可能导致实际业绩、业绩或成就与前瞻性陈述中讨论或暗示的结果存在重大差异。这些风险和不确定性包括但不限于与公司早期发展阶段、迄今为止收入不足、政府监管、其产品的市场接受度、快速的技术变革、对关键人员的依赖、对公司知识产权的保护、对公司战略合作伙伴的依赖以及公司2023年3月30日年度信息表第29至36页在 “风险因素” 标题下讨论的风险相关的风险,该表的副本可在公司的SEDAR+个人资料下找到,网址为。应仔细考虑这些因素,读者不应过分依赖前瞻性陈述。尽管本新闻稿中包含的前瞻性陈述基于管理层认为合理的假设,但公司无法向读者保证实际业绩将与这些前瞻性陈述一致。这些前瞻性陈述自本新闻稿发布之日起作出,除非法律要求,否则公司没有义务对其进行更新或修改以反映新的事件或情况。
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
多伦多证券交易所风险投资交易所及其监管服务提供商(该术语在多伦多证券交易所风险交易所的政策中定义)均不对本新闻稿的充分性或准确性承担责任。